Lilly leads the big pharma pack on pipeline value
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.
Go or no go? Apellis and Heron head for the finish line
May will see US FDA decisions for Apellis, Heron and Bristol Myers Squibb, while Provention Bio is set for a panel meeting.
Delays look like the best-case scenario for teplizumab
Picking up the Lilly cast-off might not have been an easy win for Provention after all.
Insulet comes out fighting
Pivotal data on its closed-loop insulin delivery system look good, but Medtronic remains a threat.
